139 related articles for article (PubMed ID: 24573216)
1. Growth conditions of clostridium perfringens type B for production of toxins used to obtain veterinary vaccines.
Viana Brandi I; Domenici Mozzer O; Jorge EV; Vieira Passos FJ; Lopes Passos FM; Cangussu AS; Macedo Sobrinho E
Bioprocess Biosyst Eng; 2014 Sep; 37(9):1737-42. PubMed ID: 24573216
[TBL] [Abstract][Full Text] [Related]
2. Potential protective immunogenicity of recombinant Clostridium perfringens α-β2-β1 fusion toxin in mice, sows and cows.
Zeng J; Deng G; Wang J; Zhou J; Liu X; Xie Q; Wang Y
Vaccine; 2011 Jul; 29(33):5459-66. PubMed ID: 21641956
[TBL] [Abstract][Full Text] [Related]
3. Quality assurance of C. perfringens epsilon toxoid vaccines--ELISA versus mouse neutralisation test.
Rosskopf-Streicher U; Volkers P; Noeske K; Werner E
ALTEX; 2004; 21 Suppl 3():65-9. PubMed ID: 15057410
[TBL] [Abstract][Full Text] [Related]
4. [Production of a vaccine against enterotoxemia from Clostridium perfringens strains isolated in the field].
Cherfaoui S; Kadra B
Arch Inst Pasteur Alger; 1992; 58():205-24. PubMed ID: 1309137
[TBL] [Abstract][Full Text] [Related]
5. Analysis of protection afforded by a Clostridium perfringens alpha-toxoid against heterologous clostridial phospholipases C.
Neeson BN; Clark GC; Atkins HS; Lingard B; Titball RW
Microb Pathog; 2007 Oct; 43(4):161-5. PubMed ID: 17604945
[TBL] [Abstract][Full Text] [Related]
6. Control of Clostridium perfringens vaccines using an indirect competitive ELISA for the epsilon toxin component - examination of the assay by a collaborative study.
Rosskopf-Streicher U; Volkers P; Werner E
Pharmeuropa Bio; 2004 Jan; 2003(2):91-6. PubMed ID: 14960265
[TBL] [Abstract][Full Text] [Related]
7. Effect of carbohydrates and control of culture pH on beta toxin production by Clostridium perfringens type C.
Sakurai J; Duncan CL
Microbiol Immunol; 1979; 23(5):313-8. PubMed ID: 41161
[TBL] [Abstract][Full Text] [Related]
8. Production and standardization of polyvalent Clostridium perfringens vaccine in Iran.
Ardehali M; Darakhshan H
Dev Biol Stand; 1976; 32():31-4. PubMed ID: 187509
[TBL] [Abstract][Full Text] [Related]
9. [Use of molasses and whey in culture media for the development and production of a toxin from Clostridium perfringens type D].
Silva HJ; Giulietti AM; Segovia RF; Ertola RJ
Rev Argent Microbiol; 1982; 14(2):85-90. PubMed ID: 6101000
[TBL] [Abstract][Full Text] [Related]
10. Clostridium perfringens vaccines.
Titball RW
Vaccine; 2009 Nov; 27 Suppl 4():D44-7. PubMed ID: 19837285
[TBL] [Abstract][Full Text] [Related]
11. Immunization of broiler chickens against Clostridium perfringens-induced necrotic enteritis.
Kulkarni RR; Parreira VR; Sharif S; Prescott JF
Clin Vaccine Immunol; 2007 Sep; 14(9):1070-7. PubMed ID: 17634510
[TBL] [Abstract][Full Text] [Related]
12. Selection of a Clostridium perfringens type D epsilon toxin producer via dot-blot test.
Gonçalves LA; Lobato ZI; Silva RO; Salvarani FM; Pires PS; Assis RA; Lobato FC
Arch Microbiol; 2009 Nov; 191(11):847-51. PubMed ID: 19779698
[TBL] [Abstract][Full Text] [Related]
13. Measurement of Clostridium perfringens beta-toxin production by surface plasmon resonance immunoassay.
Hsieh HV; Stewart B; Hauer P; Haaland P; Campbell R
Vaccine; 1998; 16(9-10):997-1003. PubMed ID: 9682350
[TBL] [Abstract][Full Text] [Related]
14. An
Hoonakker M; Zariri A; de Brouwer L; David D; Borgman A; Sloots A
Front Immunol; 2024; 15():1373411. PubMed ID: 38646535
[TBL] [Abstract][Full Text] [Related]
15. The enteric toxins of Clostridium perfringens.
Smedley JG; Fisher DJ; Sayeed S; Chakrabarti G; McClane BA
Rev Physiol Biochem Pharmacol; 2004; 152():183-204. PubMed ID: 15517462
[TBL] [Abstract][Full Text] [Related]
16. Heterologous protection against alpha toxins of Clostridium perfringens and Staphylococcus aureus induced by binding domain recombinant chimeric protein.
Uppalapati SR; Kingston JJ; Murali HS; Batra HV
Vaccine; 2014 May; 32(25):3075-81. PubMed ID: 24699467
[TBL] [Abstract][Full Text] [Related]
17. Production of phospholipase C (alpha-toxin), haemolysins and lethal toxins by Clostridium perfringens types A to D.
Möllby R; Holme T; Nord CE; Smyth CJ; Wadström T
J Gen Microbiol; 1976 Sep; 96(1):137-44. PubMed ID: 10344
[TBL] [Abstract][Full Text] [Related]
18. [Development of in vitro methods for the potency testing of clostridial vaccines].
Borrmann E; Schulze F; Diller R
ALTEX; 2001; 18(1):34-6. PubMed ID: 11248848
[TBL] [Abstract][Full Text] [Related]
19. A recombinant Bacillus anthracis strain producing the Clostridium perfringens Ib component induces protection against iota toxins.
Sirard JC; Weber M; Duflot E; Popoff MR; Mock M
Infect Immun; 1997 Jun; 65(6):2029-33. PubMed ID: 9169728
[TBL] [Abstract][Full Text] [Related]
20. [Standardization of the control technics of Clostridium perfringens vaccine. Use of a reference vaccine].
Bousicaux A
Dev Biol Stand; 1976; 32():45-61. PubMed ID: 187511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
